FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 420 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR 2023 ASCO Annual Meeting Research Round Up: New Research in Treating... September 28, 2023 Despite Proven Safety of HPV Vaccines, More Parents Have Concerns October 22, 2021 Fisioterapeutas en oncología October 12, 2021 Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk... March 30, 2026 Load more HOT NEWS Prize winning early detection research EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab Accepting Help During Cancer Is Hard, But It Can Benefit You... How to Provide Support as a Long-Distance Cancer Caregiver
